Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
http://ir.tesarobio.com/static-files/dd128dbe-048e-4bfe-a661...

https://www.fool.com/premium/coverage/investing/2018/09/07/h...

Its a 2b market cap, making it about 8-10x sales for Zejula. Zejula is currently indicated for 2nd, 3rd, 4th line+ for recurrence & maintenance.

Future studies for Zejula:
Quadra: solo as 4th+ line treatment (fully enrolled / completed phase 2 trial)
PRIMA: solo as 1st line for maintenance. (fully enrolled / completed phase 3 trial)
OVARIO: 1st line for maintenance in combo with avastin. phase 2, enrolling
TOPACIO: Zejula+keytruda. 1st line for treatment, recurrence, and maintenance. enrolling, phase 2.
AVANOVA: 2nd+ line for treatment combined with avastin for recurrence and maintenance. (fully enrolled / completed phase 2 trial)

Right now, its not really used as curative treatment now except for recurrence, otherwise its for maintenance after 2nd line treatment.

This can, and should, be a billion dollar plus indication. and it completely ignores all their other indications. and all their other drugs (though its really Zejula at this point, their PD1, TIM3, and LAG drugs are not quite deserving of discussion yet).

750m sales, at 8-10x sales is a triple from here. It's just frustratingly slow awaiting these clinical trials when there are so many good stocks out there right now.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.